dc.contributor.author |
Rapoport, Bernardo Leon
|
|
dc.contributor.author |
Theron, Annette J.
|
|
dc.contributor.author |
Vorobiof, Daniel A.
|
|
dc.contributor.author |
Langenhoven, Lizanne
|
|
dc.contributor.author |
Hall, Jacqueline M.
|
|
dc.contributor.author |
Van Eeden, Ronwyn I.
|
|
dc.contributor.author |
Smit, Teresa
|
|
dc.contributor.author |
Chan, Sze-Wai
|
|
dc.contributor.author |
Botha, Michael C.
|
|
dc.contributor.author |
Raats, Johann I.
|
|
dc.contributor.author |
De Necker, Margriet
|
|
dc.contributor.author |
Anderson, Ronald
|
|
dc.date.accessioned |
2021-08-27T05:34:32Z |
|
dc.date.available |
2021-08-27T05:34:32Z |
|
dc.date.issued |
2020-06 |
|
dc.description.abstract |
AIM: We investigated the prognostic potential of pretherapy measurement of the neutrophil/lymphocyte ratio (NLR) in patients (n = 56) with non-small-cell lung cancer deemed suitable for treatment with nivolumab. MATERIALS & METHODS: This was a multicenter, noninterventional, retrospective data analysis, involving five oncology centers. RESULTS: Patients with prenivolumab NLR values of <5 and ≥5 had respective median overall survival (OS) values of 14.5 and 7.02 months (p = 0.0026). Patients with ≤2 and >2 metastatic sites had median OS values of 11.4 and 6.1 months, respectively (p = 0.0174). A Cox multiple regression model revealed baseline NLR ≥5 as the only variable significantly associated with decreased OS (p < 0.0447). CONCLUSION: Pretreatment elevated NLR values are associated with poor outcomes in patients with recurrent metastatic non-small-cell lung cancer treated with nivolumab. |
en_ZA |
dc.description.department |
Immunology |
en_ZA |
dc.description.librarian |
hj2021 |
en_ZA |
dc.description.uri |
http://www.futuremedicine.com/loi/lmt |
en_ZA |
dc.identifier.citation |
Rapoport, B.L., Theron, A.J., Vorobiof, D.A., et al. 2020, ' Prognostic significance of the neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small-cell lung cancer', Lung Cancer Management, vol. 9, no. 3, art. LMT37, pp. 1-12. |
en_ZA |
dc.identifier.issn |
1758-1966 (print) |
|
dc.identifier.issn |
1758-1974 (online) |
|
dc.identifier.other |
10.2217/lmt-2020-0014 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/81521 |
|
dc.language.iso |
en |
en_ZA |
dc.publisher |
MDPI |
en_ZA |
dc.rights |
© 2020. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). |
en_ZA |
dc.subject |
Nivolumab |
en_ZA |
dc.subject |
PD-1 inhibitor |
en_ZA |
dc.subject |
Pretherapy measurement |
en_ZA |
dc.subject |
Neutrophil/lymphocyte ratio (NLR) |
en_ZA |
dc.subject |
Non-small cell lung cancer (NSCLC) |
en_ZA |
dc.title |
Prognostic significance of the neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small-cell lung cancer |
en_ZA |
dc.type |
Article |
en_ZA |